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Original Contributions and Case Studies 
Hypoglycemia After Administration of Somatostatin Analog 
(SMS 201-995) in Metastatic Carcinoid 
John E . Brunner, MD,* Davida F. Kruger, RN, C, MSN, CDE,^ 
Michael A. Basha, DO,* Eyal Meiri, MD,§ and Scott S. Kaatz, DO" 
SMS 201-995 (Sandoz Pharmaceuticals. East Hanover NJ) is a synthetic peptide analog of native 
somatostatin that has been used to relieve .symptoms caused by neuroendocrine tumors. Reports have 
described an insulin suppressive effect of SMS 201-995 that results in elevations of blood glucose. We 
report a patient with a metastatic small bowel carcinoid and renal failure in whom mild symptomatic 
hypoglycemia occurred 30 to 60 minutes after SMS 201-995 administration. No increase in insulin or 
decreases in glucagon. Cortisol, or catecholamines were observed during these hypoglycemic 
episodes. Elevated levels of growth hormone fell gradually following SMS 201-995 administration and 
did not temporally correspond to the 30- to 60-minute nadir of blood glucose. However SMS 201-995 
levels peaked during this 30- to 60-minute period. As clinical experience with this drug broadens, 
patients whose glucose control is dependent on counter-regulatory hormones should be monitored for 
the possibility of hypoglycemia. (Henry Ford Hosp Med J 1989:37:60-2) 
N ative somatostatin is a peptide hormone that inhibits multi-ple endogenous peptides and ectopic hormone secretion 
from neuroendocrine tumors. Its clinical usefulness is limited 
by its 3 minute half-life and the need for continuous intravenous 
infusion. SMS 201-995 (Sandoz Pharmaceuticals, East Han-
over, NJ) is a synthetic octapeptide which can be administered 
by subcutaneous injection and has a prolonged duration of ac-
tion (1). It has been successfully used to relieve symptoms in pa-
tients with refractory diarrhea due to the carcinoid syndrome 
(2). A side effect of SMS 201-995 is impaired glucose tolerance 
secondary to insulin suppression (3,4). We report a patient with 
metastatic small bowel carcinoid who experienced reproducible 
mild hypoglycemia after acute administration of SMS 201-995. 
Subject 
A 65-year-old black female (38.6 kg [85 lb]) with metastatic 
small bowel carcinoid, malnutrition, and dialysis-dependent 
end stage renal disease was admitted to our clinical research unit 
for treatment of her refractory diarrhea with SMS 201-995. In-
formed consent was obtained from the patient. 
A pretreatment profile was obtained after an 8-hour ovemight 
fast. Measurements of blood glucose, serotonin, insulin, and 
growth hormone were collected at -15, 0, 30, 60,90,120, 150, 
180, 210, and 240 minutes. A repeat study of blood glucose 
without SMS 201-995 was also obtained four months later. 
Doses of 100 and 200 |jLg of SMS 201-995 were administered 
subcutaneously in the fasting state. Measurements of blood 
glucose, SMS 201-995, growth hormone, growth hormone-re-
leasing hormone (GHRH), catecholamines, glucagon, Cortisol, 
and serotonin were collected at the same intervals as in the pre-
treatment day. 
Daily therapy consisted initially of 50 |jLg subcutaneously 
twice a day and was gradually increased to 150 |xg subcu-
taneously three times a day over a total of 12 weeks. 
Methods 
Tissue blocks from the original tumor resection were studied 
in a biotin-avidin-immunoperoxidase system with antibodies 
for growth hormone, G H R H , serotonin, and pancreatic 
polypeptide. 
Radioimmunoassay (RIA) measurements for SMS 201-995, 
pancreatic polypeptide, and glucagon levels were performed by 
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BLOOD GLUCOSE (BG), GROWTH HORMONE (GH), INSULIN (I), GLUCAGON AND SMS 201-995. 
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Figure—Left panel: Fasting blood glucose (BG), growth hormone (GH), and insulin (I) without SMS 201-995 during a 240-minute 
period of observation. Right panel: Blood glucose, growth hormone, insulin, SMS 201-995, and glucagon after a single sub-
cutaneous injection of200 |xg of SMS 201-995 at time 0. 
DT. Thomas O'Dorisio, Ohio State University, Columbus, OH. 
GHRH assays were performed by Dr. Lawrence Frohman, Uni-
versity of Cincinnati. Growth hormone was measured with the 
Quantitope HGH kit (Kallestad Diagnostics, Austin, TX). In-
sulin was measured by RIA. Somatomedin C was measured by 
the Nichols Institute (San Juan Capistrano, CA). Serotonin lev-
els were collected in tubes containing EDTA and ascorbic acid 
and measured by Smith Kline Bio-Science Laboratories (Van 
Nuys, CA) by a fluorometric method. Blood glucose was mea-
sured with a YSI model 23A glucose analyzer (Yellow Springs, 
OH). Plasma catecholamines were measured by high-pressure 
liquid chromatography. 
Results 
In two baseline studies without SMS 201-995, the blood 
glucose remained stable over 240 minutes (Figure [left panel]). 
During three separate challenges with SMS 201-995, blood 
glucose began to fall by 30 minutes and reached a nadir at 60 
minutes of 47, 44, and 38 mg/dL, respectively (Figure [right 
panel]). During these episodes of blood glucose reduction, the 
patient experienced sensations of weakness, hunger, tachycar-
dia, and sweats that resolved spontaneously. This symptomatic 
hypoglycemia occurred at peak SMS 201-995 levels (Figure 
[right]). Insulin levels remained under 4 |j,U/mL at all times. 
Glucagon remained elevated (mean ± SD = 323 ± 17.1 pg/ 
mL) and did not change during the 240-minute observation 
period after SMS 201-995 administration. Cortisol did not fall, 
and catecholamines remained stable until 60 minutes when they 
rose above baseline values, presumably in response to 
hypoglycemia. 
A fasting growth hormone level of 42 ng/mL was higher than 
we had expected. Evaluation of the tumor with immunoperox-
idase staining revealed only serotonin immunoreactivity. The 
patient had no somatic features of acromegaly. Somatomedin C 
levels were normal at 1.5 U/mL (normal = 0.45 to 2.2 U/mL), 
and GHRH was not elevated at 18.7 pg/mL (normal = < 25 pg/ 
mL). In the pretreatment state, a gradual spontaneous 29% re-
duction in growth hormone occurred over 240 minutes (Figure 
[left]). In response to SMS 201-995, there was a gradual 72% 
reduction in growth hormone over the 240-minute observation 
period (Figure [right]) with no discernible nadir correlating with 
the nadir in blood glucose. 
During chronic analog treatment, no decrease in diarrhea oc-
curred and plasma serotonin levels were unchanged. In the fed 
state the patient reported no symptomatic episodes of 
hypoglycemia. 
Discussion 
The purpose of treatment with SMS 201-995 in this patient 
was to decrease her diarrhea and possibly promote tumor regres-
sion. Neither of these responses was observed. The inability to 
reduce stool volume may have been due to a short bowel syn-
drome from previous intestinal resections and a lack of tumor 
receptors for somatostatin. 
The anticipated response to SMS 201-995 is a rise in blood 
glucose due to the insulin suppressive effect of the analog (3-6). 
The reduction in blood glucose which we observed may occur 
through several mechanisms. For example, in type 1 insulin-de-
pendent diabetes mellitus, reductions in postprandial blood 
glucose have been described with the administration of 
somatostatin analogs and native somatostatin (7,8). This has 
been explained by the inhibitory effects of somatostatin on 
glucagon and on bowel nutrient absorption (7,8). Infusions of 
Henry Ford Hosp Med J—Vol 37, No 2, 1989 Hypoglycemia with SMS 201-995—Brunner et ai 61 
native somatostatin have also been used to lower the blood 
glucose in diabetic ketoacidosis where large elevations in 
glucagon and growth hormone are thought to contribute to the 
hyperglycemia and ketogenesis (9). However, we did not ob-
serve a reduction in glucagon (Figure [right]), and insulin re-
mained suppressed throughout all studies. 
Patients with multiple liver metastasis, renal failure, and mal-
absorption and malnutrition due to diarrhea are subject to symp-
tomatic hypoglycemia due to reduced glycogen stores and im-
paired gluconeogenic processes (10). Maintenance of adequate 
blood glucose levels in the fasting state requires counter-reg-
ulatory elevations in growth hormone and glucagon. Inhibition 
of growth hormone by SMS 201-995 may have caused blood 
glucose to decline. However, the reduction in growth hormone 
did not temporally parallel the glucose nadir during the 30- to 
60-minute period. Another possible mechanism for the decrease 
in blood glucose may have been the inhibition of bowel nutrient 
absorption, but this patient's diarrhea, rapid gastrointestinal 
transit time, and fasting state should have minimized this effect. 
Temporally, SMS 201-995 was peaking during the 30- to 60-
minute period when blood glucose was reaching its nadir. An 
insulin-like action of SMS 201-995 or suppression of another 
unknown glucose regulating process could explain this 
phenomenon. 
Hypoglycemia did not occur if the analog was administered 
after the patient had been fed. Other patients whose glucose 
homeostasis may be tenuous or dependent on counter-regulatory 
hormones should be monitored for hypoglycemia after admin-
istration of SMS 201-995 in the fasting state. 
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